Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Climb Bio announced promising initial Phase 1 safety and pharmacometric modeling data for CLYM116, its anti-APRIL monoclonal antibody targeting IgA nephropathy (IgAN). The favorable safety profile in healthy volunteers supports continued clinical development. The company plans further data presentations and expects dosing initiation in IgAN patient…